BIO-RAD LABORATORIES, INC. — Director's Dealing 2020

Nov 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-RAD LABORATORIES, INC. (BIO BIOB)
CIK: 0000012208
Period of Report: 2020-11-06

Reporting Person: TUMOLO ANNETTE (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-06	Bio-Rad A Common Stock	M	1200	$159.32	Acquired	5322.3476	Direct
2020-11-06	Bio-Rad A Common Stock	S	220	$639.62	Disposed	5102.3476	Direct
2020-11-06	Bio-Rad A Common Stock	S	734	$640.78	Disposed	4368.3476	Direct
2020-11-06	Bio-Rad A Common Stock	S	246	$641.53	Disposed	4122.3476	Direct
2020-11-09	Bio-Rad A Common Stock	G	423	—	Disposed	3699.3476	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-06	Non-Qualified Stock Option (right to buy)	$159.32	M	1200	Disposed	2026-09-07	Bio-Rad A Common Stock (1200)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $639.16 to $640.14, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $640.24 to $641.19, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $641.50 to $641.92, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted.